Almac Sciences: “First in man” approach to peptides
05 Dec 2007. Building on just one of its widely-acknowledged strengths – in peptide synthesis – Almac Sciences (Hall 16 Stand A75) is taking the opportunity of CPhI 2007 to position its “First in Man” approach.
This embraces and offers development of peptide synthesis, full analytical support (including method development and validation, reference standard, QA release and stability studies); GMP batches for Phase I and II (scaling from grammes to several kgs.), and finally support with CMC documentation.
It also stresses the strong connectivity between its cGMP peptide offering and other specialist capabilities within Almac Sciences – including 14C radiolabelling, cytotoxic conjugation and sterile formulation and filling.
Almac Sciences has capability to produce hundreds of peptides per month including conjugation to carrier protein if required. Bespoke custom work can typically include mgs to low gs, with cGMP at low kgs. A product listing includes natural/modified chemokines, with a specialization in long chain peptide synthesis. API production capacity is up to 100s g/batch.
Chemical synthesis capability:
In development of site-specific chemical modification of proteins, chemical synthesis of peptides and proteins has proved especially powerful. It enables numerous side-chain and backbone site-specific modifications to be incorporated into the primary sequence – providing a route for the increasingly sophisticated peptides required by the bio-community.
Almac Sciences has successfully developed a suite of both native and site-specifically modified chemokines. These have broad applications across research and drug discovery and are integral to methods employed by pharma and biotech to accelerate drug discovery.
Combining improved solid-phase synthetic methodology for step-wise chain assembly, tag based purification methods, peptides can be synthesised in high yield.
Service connectivity:
Almac Sciences has strong connectivity between its cGMP peptide offerings and other in-house niche capabilities. These include 14C radiolabelling, with several complex peptide and radiolabelling projects completed, together with cytotoxic conjugations to peptides, and sterile formulation and finishing.
Sterile formulation and filling is through partnership in the US with with Coldstream Laboratories, Lexington, Kentucky. This provides IV formulation and sterile fill for clinical trial applications through its innovative sterile manufacturing facility at the Research Campus, near Lexington.
The company is currently looking to add a European partner for sterile formulation and finishing, with an announcement expected within the next few months.
Part of the Almac Group, Almac Sciences is distinct for its capability to make very long peptides (60 – 100 mer) to GMP. The company’s main facility is its 80,000 sq. ft., £25m. HQ and laboratory complex in Craigavon, Northern Ireland, with additional R&D facilities near Edinburgh, Scotland.
Peptide Service offering:
- Services include Clinical grade peptide supply, conforming to GMP ICHQ7A, with supporting development/documentation, with analytical packages and a stability package to support IND. Production is focused through a scale up GMP lab and small scale GMP lab, employing solid phase peptide Synthesis Technology, Fmoc chemistry for long peptides and in-process UV monitoring of coupling and de-protection.
- In Purification Technology, RP-HPLC is employed for initial peptide purification, with API purity tailored to customer requirements (High Purity API 95 -99.9%). Isolation is via Lyophilisation in class 100,000 clean room, with Class 100,000 and 10,000 facilities for freeze drying of API and packaging in a class 10,000 environment
- Scale up and optimization strategy is focused on developing/optimizing all areas of the total process, with emphasis (eg) on purification and freeze drying time to enhance throughput and serve the cost-of-goods agenda.
About Almac
The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, translational genomic services, API manufacture, formulation development, clinical trial supply and technology (IVRS/EDC), to commercial-scale manufacture. Almac provides services to over 600 companies including all the world leaders in the pharmaceutical and biotech sectors. The company is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California.
Contact: Dr Rosaleen McGuckin
T: + 44 (0)28 3833 2200